Although a substantial amount of the literature suggests the beneficial effects of EZH2 inhibition in combination with cisplatin therapy in different cancer types, reports exist documenting the inverse relationship of EZH2 and cisplatin resistance. This evidence concerns the gene EZH2 and cancer.